Skip to content

Effects of Lycra Suits in Children With Cerebral Palsy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02712021
Acronym
CP
Enrollment
10
Registered
2016-03-17
Start date
2016-04-30
Completion date
2016-12-31
Last updated
2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Keywords

Cerebral Palsy, Lycra, Motor Function, Static Balance

Brief summary

Lycra garments have recently been used for children with cerebral palsy, with favorable effects on alignment, biomechanics and neuromuscular activity. The aim of the present study is to determine the efficacy of a Lycra suit in improving motor function and static balance in children with cerebral palsy. The children included in this study will be part of a prospective project on children with cerebral palsy, older than 4 years of age, and their families regularly followed at the Child Neurology Unit of the Catholic University of Rome.

Detailed description

A total of 10 children with cerebral palsy will be recruited and included in the study. Five of them will be considered as study group and will wear a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The other 5 will be considered as control group, matched for age and sex to the study group, and will not wear the lycra suit. The evaluation of static balance and the gross motor function measure will be used as outcome measure. The children of both groups will be assessed twice, at baseline and 6 months after, each child acting as his/her own control. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.

Interventions

OTHERLycra suit and physiotherapy treatment

Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).

All the children will be involved in regular physiotherapy treatment (2-3/week).

Sponsors

Catholic University, Italy
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Confirmed diagnosis of cerebral palsy based on the predominant type of motor impairment and classified according to the criteria proposed by Himmelmann.

Exclusion criteria

* Presence of major congenital malformations or metabolic or haematological complications. * The investigators will also exclude children who had previously worn a lycra garment and who received Botulinum toxin injections or orthopaedic surgery in the year before the study.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline evaluation of static balance at 6 monthsThe children were assessed twice, at baseline and 6 months after, each child acting as his/her own control.The evaluation of static balance will be assessed by a seated stabilometry exam performed on a Prokin PK 254 P device produced by TecnoBody S.r.l. (Dalmine BG - Italy). This device consists of a static plate (47 centimeters of circumference) equipped internally with four piezoelectric sensors positioned at the extremity of the four cardinals points.

Secondary

MeasureTime frameDescription
Change from baseline Gross Motor Function Classification System at 6 monthsThe children were assessed twice, at baseline and 6 months after, each child acting as his/her own control.The Gross Motor Function Measure (GMFM) will be used to evaluate gross motor function quantitatively. The GMFM consists of 88 items grouped into 5 dimensions: A (lying and rolling), B (sitting), C (crawling and kneeling), D (standing), E (walking, running and jumping). Scores for each dimension are expressed as a percentage of the maximum score for that dimension. A total score is obtained by adding the scores for all dimensions and dividing by 5, ranging from 0 to 100.

Contacts

Primary ContactDomenico Romeo, MD, PhD
domenicomarco.romeo@policlinicogemalli.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026